Editorial Article: Accelerated production of novel immunotherapies with high-throughput screening
Dr. Dallas Flies, Vice President, Discovery Research, NextCure, Inc. discusses the cutting-edge technology transforming the identification of new targets for the development of effective immunotherapeutics
29 Jul 2021
Dr. Dallas Flies, Vice President, Discovery Research, NextCure, Inc.
A major challenge in the development and production of immunotherapeutics is the shortage of novel targets that can be exploited. To tackle this, NextCure, a fully integrated clinical-stage biopharmaceutical company, is working hard to accelerate the development of cancer therapeutics and improve patient care, by identifying potential targets through advanced high-throughput screening techniques such as flow cytometry and cell sorting.
Accelerated production of novel immunotherapies selectscience.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from selectscience.net Daily Mail and Mail on Sunday newspapers.
5 min read
By OKECHUKWU PEACE
Dr. Samuel Achilefu, professor and Ghief of the optical radiology lab at Washington University School of Medicine, was honored with the 2014 St. Louis Award for his contributions to cancer treatment research.
Born to Nigerian parents during the Biafran War, he helped developed high-tech glasses that help surgeons visualize cancer cells during surgery. He is the 87th recipient of the award, established in 1931 by leading philanthropist David Wohl.
Here are some facts about the scholar… Samuel Achilefu, PhD was age five years old when the Biafran civil war forced his family to move to a safer area in Nigeria and start life anew.